Nuclea Biotechnologies specializes in utilizing the study of gene and protein expression to create a better understanding of the effectiveness of treatments for various diseases, including cancer and congestive heart failure. Nuclea Biotechnologies uses information on protein and gene makeup as a way to target treatments and assess their effectiveness. The company has developed innovative tests in regards to identifying patient response to treatments. These tests also aid in predicting the possibility of a recurrence of the disease. Nuclea Biotechnologies employs technologies that allow a deeper understanding of the biology of human disease. This information helps evaluate new forms of treatment.